SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Jubilant Life Sciences surges as its arm inks long term contracts in Radiopharma business

04 Jan 2017 Evaluate

Jubilant Life Sciences is currently trading at Rs. 664.00, up by 26.15 points or 4.10% from its previous closing of Rs. 637.85 on the BSE.

The scrip opened at Rs. 639.25 and has touched a high and low of Rs. 674.00 and Rs. 638.00 respectively. So far 1,14,000 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 726.40 on 01-Dec-2016 and a 52 week low of Rs. 272.50 on 20-Jan-2016.

Last one week high and low of the scrip stood at Rs. 674.00 and Rs. 602.35 respectively. The current market cap of the company is Rs. 10,578.66 crore.

The promoters holding in the company stood at 54.02%, while Institutions and Non-Institutions held 26.26% and 19.72% respectively.

Jubilant Life Sciences’ wholly own subsidiary Jubilant Pharma, through one of its units Jubilant DraxImage Inc. Montreal Canada (JDI), has signed long term contracts with distribution networks in the US for supply of products used for diagnostic and therapeutic procedures for thyroid, myocardial perfusion, lung, kidney and bone scans to be supplied by JDI over a period of 39 months effective from January 2017.

Jubilant Life Sciences is an integrated global Pharmaceutical and Life Sciences Company engaged in manufacture and supply of APIs, Solid Dosage Formulations, Radiopharmaceuticals, Allergy Therapy Products and Life Science Ingredients.



Jubilant Pharmova Share Price

904.40 -7.20 (-0.79%)
20-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.00
Dr. Reddys Lab 1232.25
Cipla 1228.90
Zydus Lifesciences 936.35
Lupin 2328.60
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×